WO1996015262A3 - Method for the detection of ras oncogenes, in particular the 12-ras oncogene - Google Patents

Method for the detection of ras oncogenes, in particular the 12-ras oncogene Download PDF

Info

Publication number
WO1996015262A3
WO1996015262A3 PCT/GB1995/002644 GB9502644W WO9615262A3 WO 1996015262 A3 WO1996015262 A3 WO 1996015262A3 GB 9502644 W GB9502644 W GB 9502644W WO 9615262 A3 WO9615262 A3 WO 9615262A3
Authority
WO
WIPO (PCT)
Prior art keywords
ras
detection
restriction site
ras oncogene
oncogene
Prior art date
Application number
PCT/GB1995/002644
Other languages
French (fr)
Other versions
WO1996015262A2 (en
Inventor
Jarle Breivik
Gustav Gaudernack
Original Assignee
Medinnova Sf
Dzieglewska Hanna Eva
Jarle Breivik
Gustav Gaudernack
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medinnova Sf, Dzieglewska Hanna Eva, Jarle Breivik, Gustav Gaudernack filed Critical Medinnova Sf
Priority to DE69525468T priority Critical patent/DE69525468D1/en
Priority to EP95936662A priority patent/EP0791074B1/en
Priority to JP8515836A priority patent/JPH10508746A/en
Priority to US08/836,329 priority patent/US6090546A/en
Priority to AU38514/95A priority patent/AU704784B2/en
Priority to AT95936662T priority patent/ATE213276T1/en
Publication of WO1996015262A2 publication Critical patent/WO1996015262A2/en
Publication of WO1996015262A3 publication Critical patent/WO1996015262A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
  • Led Device Packages (AREA)
  • Debugging And Monitoring (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to an oligonucleotide primer sequence for use in in vitro amplification, characterised in that said primer sequence is capable of creating a BstX I restriction site overlapping codon (12) and/or an Xcm I restriction site overlapping codon (13) or a Bce 83I restriction site overlapping codon (61) of the wild-type K-ras oncogene, methods of using said primer sequences for detecting activating mutations in codons (12 and/or 13 and/or 61) of the K-ras oncogene and kits for performing the methods.
PCT/GB1995/002644 1994-11-11 1995-11-10 Method for the detection of ras oncogenes, in particular the 12-ras oncogene WO1996015262A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE69525468T DE69525468D1 (en) 1994-11-11 1995-11-10 METHOD FOR DETECTING RAS ONCOGENES, IN PARTICULAR THE K-RAS ONCOGEN
EP95936662A EP0791074B1 (en) 1994-11-11 1995-11-10 Method for the detection of ras oncogenes, in particular the k-ras ancogene
JP8515836A JPH10508746A (en) 1994-11-11 1995-11-10 Method for detecting ras oncogene, especially K-ras oncogene
US08/836,329 US6090546A (en) 1994-11-11 1995-11-10 Method for the detection of Ras oncogenes, in particular the K-ras oncogene
AU38514/95A AU704784B2 (en) 1994-11-11 1995-11-10 Method for the detection of ras oncogenes, in particular the K-ras oncogene
AT95936662T ATE213276T1 (en) 1994-11-11 1995-11-10 METHOD FOR DETECTING RAS ONCOGENES, IN PARTICULAR THE K-RAS ONCOGEN

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9422814A GB9422814D0 (en) 1994-11-11 1994-11-11 Chemical method
GB9422814.5 1994-11-11

Publications (2)

Publication Number Publication Date
WO1996015262A2 WO1996015262A2 (en) 1996-05-23
WO1996015262A3 true WO1996015262A3 (en) 1996-08-15

Family

ID=10764263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1995/002644 WO1996015262A2 (en) 1994-11-11 1995-11-10 Method for the detection of ras oncogenes, in particular the 12-ras oncogene

Country Status (9)

Country Link
US (1) US6090546A (en)
EP (1) EP0791074B1 (en)
JP (1) JPH10508746A (en)
AT (1) ATE213276T1 (en)
AU (1) AU704784B2 (en)
CA (1) CA2205017A1 (en)
DE (1) DE69525468D1 (en)
GB (1) GB9422814D0 (en)
WO (1) WO1996015262A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US6780583B1 (en) 1996-07-19 2004-08-24 Board Of Trustees Operating Michigan State University DNA encoding canine von willebrand factor and methods of use
US6767707B2 (en) 1996-07-19 2004-07-27 University Of Michigan DNA encoding canine von willebrand factor and methods of use
EP0961836B1 (en) * 1996-07-19 2005-09-21 The Regents Of The University Of Michigan Dna encoding canine von willebrand factor and methods of use
US20030129589A1 (en) * 1996-11-06 2003-07-10 Hubert Koster Dna diagnostics based on mass spectrometry
US6410237B1 (en) 1997-07-18 2002-06-25 Board Of Trustees Operating Michigan State University DNA encoding canine von Willebrand factor and methods of use
DE19736691A1 (en) * 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Characterising and identifying disseminated metastatic cancer cells
US7014994B1 (en) 1999-03-19 2006-03-21 Cornell Research Foundation,Inc. Coupled polymerase chain reaction-restriction-endonuclease digestion-ligase detection reaction process
CA2369533A1 (en) * 1999-03-19 2000-09-28 Francis Barany Coupled polymerase chain reaction-restriction endonuclease digestion-ligase detection reaction process
ATE278035T1 (en) * 1999-05-04 2004-10-15 Ortho Clinical Diagnostics Inc FAST AND EFFECTIVE DNA IMMOBILIZATION FROM A SAMPLE WITHOUT THE USE OF CELL LYSIS REAGENTS
US7262006B1 (en) 2000-05-01 2007-08-28 Ortho-Clinical Diagnostics, Inc. Rapid and efficient capture of DNA from sample without using cell lysing reagent
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
KR101241272B1 (en) * 2002-12-16 2013-03-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 Yeast-based vaccines as immunotherapy
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
AU2005295317B2 (en) * 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CA2647102A1 (en) * 2006-03-27 2007-11-22 Globeimmune, Inc. Ras mutation and compositions and methods related thereto
IL282783B2 (en) 2006-05-18 2023-09-01 Caris Mpi Inc System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
DE102008029356A1 (en) * 2008-06-20 2009-12-24 Siemens Healthcare Diagnostics Gmbh Process for the purification of nucleic acids, in particular from fixed tissue
JP2012503011A (en) 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド Immunotherapy of chronic hepatitis C virus infection
CN101381779B (en) * 2008-10-21 2011-06-08 广州益善生物技术有限公司 Detection probe of kRas gene mutation, liquid phase chip and detection method thereof
BRPI0921043A2 (en) * 2008-11-12 2018-08-07 Caris Life Sciences Luxembourg Holdings methods and systems for using exosomes to determine phenotypes
DE102008061714A1 (en) * 2008-12-12 2010-06-17 Siemens Healthcare Diagnostics Inc., Deerfield Process for the purification of nucleic acids, in particular from fixed tissue
JP5808349B2 (en) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー Biomarkers for theranosis
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
WO2014052613A2 (en) * 2012-09-26 2014-04-03 Insight Genetics, Inc. Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers
WO2022203981A1 (en) * 2021-03-22 2022-09-29 The Johns Hopkins University K-ras inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466083A2 (en) * 1990-07-09 1992-01-15 E.R. SQUIBB & SONS, INC. Method for site-directed mutagenesis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155316C (en) * 1982-04-23 1987-03-11 Sintef PROCEDURE FOR MAKING MAGNETIC POLYMER PARTICLES.
KR920700360A (en) * 1989-03-22 1992-02-19 하리크 프리드리히 Sliding bearing
JPH04235919A (en) * 1991-01-17 1992-08-25 Sankyo Co Ltd Anticancer drug
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
WO1992015680A1 (en) * 1991-03-06 1992-09-17 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
DK0537008T3 (en) * 1991-10-11 1995-12-04 Squibb & Sons Inc Use of bisphosphates to prepare a drug to block neoplastic transformation of cell induced by ras oncogenes
GB9323305D0 (en) * 1993-11-11 1994-01-05 Medinnova Sf Isoaltion of nucleic acid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466083A2 (en) * 1990-07-09 1992-01-15 E.R. SQUIBB & SONS, INC. Method for site-directed mutagenesis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JACOBSON D ET AL: "Rapid nonradioactive screening for activating ras oncogene mutations using PCR-primer introduced restriction analysis (PCR-PIRA)", PCR METHODS AND APPLICATIONS, vol. 1, no. 2, 1991, pages 146 - 48, XP000572412 *
LIN S ET AL: "mutation analysis of K-ras oncogenes in gasteroenterologic cancers by the amplified created restriction sites method", AM. J. CLIN. PATHOL, vol. 100, no. 6, December 1993 (1993-12-01), pages 686 - 89, XP000572107 *
MITSUDOMI T ET AL: "Mutations of ras genes distinguish a subset of non-small-cell lung cancer lines from small-cell cancer cell lines", ONCOGENE, vol. 6, no. 8, 1991, pages 1353 - 62, XP002004427 *

Also Published As

Publication number Publication date
JPH10508746A (en) 1998-09-02
ATE213276T1 (en) 2002-02-15
AU704784B2 (en) 1999-05-06
WO1996015262A2 (en) 1996-05-23
GB9422814D0 (en) 1995-01-04
US6090546A (en) 2000-07-18
AU3851495A (en) 1996-06-06
EP0791074B1 (en) 2002-02-13
CA2205017A1 (en) 1996-05-23
DE69525468D1 (en) 2002-03-21
EP0791074A2 (en) 1997-08-27

Similar Documents

Publication Publication Date Title
WO1996015262A3 (en) Method for the detection of ras oncogenes, in particular the 12-ras oncogene
DE69332642D1 (en) METHODS FOR DETECTING MICROMETASAS IN PROSTATE CANCER
EP0357611A4 (en) A method of detection of carcinogenic human papillomavirus
DE3588250D1 (en) Method for detecting a single-stranded genetic target material
HK1033765A1 (en) Detection of neoplasia by analysis of saliva
DE69003104D1 (en) METHOD FOR DETECTING SPECIFIC SEQUENCES OF NUCLEIC ACIDS AND THEIR USE.
EP0589424A3 (en) Shape steel material having high strength, high toughness and excellent fire resistance and process for producing rolled shape steel of said material
DE69008182D1 (en) COMPOSITION AND METHOD FOR CHROMING GALVANIZED STEEL AND SIMILAR MATERIALS.
AU6659698A (en) Compositions, methods, kits and apparatus for determining the presence or absence of target molecules
FI955415A (en) MTS gene, its mutations and methods for detecting cancer using MTS gene sequences
DE59606475D1 (en) Process for the production of alloyed steels and electric furnace system with adjustable fresh lances therefor
AU2135497A (en) Genetic markers and methods for the detection of escherichia coli serotype-0157:h7
AU7326494A (en) Nucleotide sequences and process for amplifying and detection of hepatitis b virus
SG63589A1 (en) Diagnostic compositions elements methods and test kits for amplification and detection of two or more dna's using primers having matched melting temperatures
AU5100798A (en) Genetic markers and methods for the detection of (listeria monocytogenes) and (listeria spp)
WO2001042792A3 (en) Diagnosis of cervical cancer using marker proteins
DE69011927D1 (en) Steel pipe, method of welding the same and carbon dioxide corrosion resistant pipe.
DE69506704D1 (en) METHOD AND SAMPLES FOR DETECTING MARKERS ASSOCIATED WITH THE LOCUS OF INFANTILE SPINALAMYOTROPHIES
AU6884596A (en) Systematic extraction, amplification and detection of retroviral sequences, and oligonucleotides for use therein
AU4327593A (en) Methods for amplification of genome and mixtures of initiator oligonucleotides for the detection and identification of related genomic sequences
NO20021196L (en) A method for detecting oxidized forms of guanylate cyclase and a method for screening dexterity activators of soluble guanylate cyclase with oxide inhibitor iron
DE59704145D1 (en) METHOD FOR CHROMING AND / OR DEPOSITING THE MgO CONTENT OF STEEL SLAG
AU1911395A (en) Method, reagent and kit for the detection and amplification of nucleic acid sequences
AU4602199A (en) Method for identifying and representing interindividual differences of dna sequences
Bao et al. Determination of Steel 30 CrMoV CCT Diagram

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2205017

Country of ref document: CA

Ref country code: CA

Ref document number: 2205017

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1995936662

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08836329

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1995936662

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1995936662

Country of ref document: EP